Antihistamine updosing reduces disease activity in patients with difficult-to-treat cholinergic urticaria Katja Koch, Karsten Weller, MD, Andreas Werner,

Slides:

Advertisements

Similar presentations

Early exposure to cow's milk protein is protective against IgE-mediated cow's milk protein allergy Yitzhak Katz, MD, Nelly Rajuan, MSc, Michael R. Goldberg,

Advertisements

Control of immunopathology during chikungunya virus infection Caroline Petitdemange, PhD, Nadia Wauquier, PhD, Vincent Vieillard, PhD Journal of Allergy.

D-dimer: A biomarker for antihistamine-resistant chronic urticaria

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD

What drives prescription patterns in pediatric asthma management?

Risk of an asthma exacerbation after bariatric surgery in adults

Anne M. Fitzpatrick, PhD, MSCR, W. Gerald Teague, MD

Pharmacologic rationale for treating allergic and nonallergic rhinitis

Responsiveness and minimal important difference of the urticaria control test Tatevik Ohanyan, MD, Nicole Schoepke, MD, Bediha Bolukbasi, MD, Martin Metz,

The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria Marcus Maurer, MD, Allen Kaplan, MD, Karin Rosén, MD, PhD, Michael Holden,

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD

Efficacy and safety of canakinumab in Schnitzler syndrome: A multicenter randomized placebo-controlled study Karoline Krause, MD, Athanasios Tsianakas,

Stephen J. Fowler, MD, Gaël Tavernier, PhD, Robert Niven, MD

Complete remission in 3 of 3 anti-IL-6–treated patients with Schnitzler syndrome Karoline Krause, MD, Eugen Feist, MD, Michael Fiene, MD, Tilmann Kallinich,

Dorothy M. Ryan, MD, Stephen J. Fowler, MD, Robert M. Niven, MD

Incident asthma and Mycoplasma pneumoniae: A nationwide cohort study

Is 9 more than 2 also in allergic airway inflammation?

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD

Practice Notes from the AAAI

An Infant with Atopic Dermatitis and Itching After Ingestion of Milk

Omalizumab is effective in cold urticaria—results of a randomized placebo-controlled trial Martin Metz, MD, Andrea Schütz, MD, Karsten Weller, MD, Marina.

High-dose desloratadine decreases wheal volume and improves cold provocation thresholds compared with standard-dose treatment in patients with acquired.

Keith J. Simons, PhD, Margherita Strolin Benedetti, PhD, F. Estelle R

Lieuwe D. Bos, MSc, PhD, Peter J. Sterk, MD, PhD, Stephen J

A focused parameter update: Hereditary angioedema, acquired C1 inhibitor deficiency, and angiotensin-converting enzyme inhibitor–associated angioedema

Treatment of chronic autoimmune urticaria with omalizumab

A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine–refractory chronic idiopathic urticaria

Ganesa Wegienka, PhD, Suzanne Havstad, MA, Edward M

Peter M. Wolfgram, MD, David B. Allen, MD

William J. Calhoun, MD, Tmirah Haselkorn, PhD, Dave P

Ordinary vibratory angioedema is not generally associated with ADGRE2 mutation Zuotao Zhao, MD, PhD, Sascha Reimann, MD, Shan Wang, MD, Yuhan Wang, MD,

Symptom-based classification of wheeze: How does it work in infants?

Time for a paradigm shift in asthma treatment: From relieving bronchospasm to controlling systemic inflammation Leif Bjermer, MD Journal of Allergy.

Tolerated wasp sting challenge improves health-related quality of life in patients allergic to wasp venom Jörg Fischer, MD, Martin Teufel, MD, Alexandra.

News & Notes Journal of Allergy and Clinical Immunology

Atopic dermatitis: A practice parameter update 2012

Food allergy: A review and update on epidemiology, pathogenesis, diagnosis, prevention, and management Scott H. Sicherer, MD, Hugh A. Sampson, MD Journal.

Biosimilars and drug development in allergic and immunologic diseases

Justin R. Chen, MD, Brett L. Buchmiller, MD, David A. Khan, MD

A cluster-randomized trial shows telephone peer coaching for parents reduces children's asthma morbidity Jane M. Garbutt, MB, ChB, Yan Yan, MD, PhD,

Sharon Seth, MD, David A. Khan, MD

What is an “eosinophilic phenotype” of asthma?

Onset of action of pimecrolimus cream 1% in the treatment of atopic eczema in infants Roland Kaufmann, MD, Regina Fölster-Holst, MD, Peter Höger, MD,

Cephalosporin Side Chain Cross-reactivity

Medication use in children with asthma in Finland from 1995 to 2006

Jeffrey M. Harris, MD, PhD, Christopher R

Granulomatous-lymphocytic Interstitial Lung Disease in a Patient with Common Variable Immunodeficiency Phil Lieberman, MD, John Routes, MD The Journal.

H. William Kelly, PharmD Journal of Allergy and Clinical Immunology

Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria Janine Gericke, PhD, Martin Metz, MD, Tatevik Ohanyan,

Real-life treatment of cholinergic urticaria with omalizumab

Autophagy: Nobel Prize 2016 and allergy and asthma research

Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment

Advances in the approach to the patient with food allergy

High prevalence of severe asthma in a large random population study

New pathways for itching in patients with atopic dermatitis?

Syk expression and IgE-mediated histamine release in basophils as biomarkers for predicting the clinical efficacy of omalizumab Donald W. MacGlashan,

Topical cyclosporine prevents seasonal recurrences of vernal keratoconjunctivitis in a randomized, double-masked, controlled 2-year study Alessandro.

Risk of oral food challenges

Pınar Uysal, MD, Esben Eller, MSc, PhD, Charlotte G

Measles and immunomodulation

Guus A. Westerhof, MD, Elise M. Vollema, MD, Els J

Macrolide antibiotics and asthma treatment

Asthma: The past, future, environment, and costs

The natural history of milk allergy in an observational cohort

Interrupting IL-6–receptor signaling improves atopic dermatitis but associates with bacterial superinfection Alexander A. Navarini, MD, PhD, Lars E.

Environmental factors and eosinophilic esophagitis

News Beyond Our Pages Journal of Allergy and Clinical Immunology

Natural history of cow’s milk allergy

Primary prevention of asthma and allergy

Itching as a systemic disease

Presentation transcript:

Antihistamine updosing reduces disease activity in patients with difficult-to-treat cholinergic urticaria Katja Koch, Karsten Weller, MD, Andreas Werner, MD, Marcus Maurer, MD, Sabine Altrichter, MD Journal of Allergy and Clinical Immunology Volume 138, Issue 5, Pages 1483-1485.e9 (November 2016) DOI: 10.1016/j.jaci.2016.05.026 Copyright © 2016 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 1 Less than half of all patients with CholU treated with high-dose antihistamines experience complete protection. Five categories of improvement are depicted, and proportions of patients in each category are shown. Absolute numbers of patients are shown in parentheses. A, Thirty-nine percent, 43%, and 46% of patients with CholU had 50% or greater improvement with high-dose antihistamines in the CholUAS7 score, the composite pruritus score 7 (CholPruritus7), and the composite wheal score 7 (CholWheal7), respectively. B, Only 7% of patients with CholU had 50% or greater improvement in the UASprovo score. Improvement was primarily seen in itch severity (36%) but not in wheal intensity (4%). C, Thirty-nine percent of the patients with CholU reported a DLQI score reduction of 50% or greater. CholUAS7 = 7-day sum of ([Whealday + Itchday] × Intensity of Elicitorday); range = 0 to 168. CholPruritus7 = 7-day sum of (Pruritusday × Intensity of Elicitorday); range = 0 to 84. CholWheal7 = 7-day sum of (Whealday × Intensity of Elicitorday); range = 0 to 84. UASprovo = Whealprovo + Itchprovo; range = 0 to 6. Pruritusprovo: range = 0 to 3. Whealprovo: range = 0 to 3. DLQI: range = 0-30 (no impairment = 0-1 points; mild impairment = 2-5 points; moderate impairment = 6-10 points; very large impairment = 11-20 points; and extremely large impairment = 21-30 points). Journal of Allergy and Clinical Immunology 2016 138, 1483-1485.e9DOI: (10.1016/j.jaci.2016.05.026) Copyright © 2016 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig E1 Study flow chart. UASprovo, Urticaria activity score after PCE provocation testing. Journal of Allergy and Clinical Immunology 2016 138, 1483-1485.e9DOI: (10.1016/j.jaci.2016.05.026) Copyright © 2016 American Academy of Allergy, Asthma & Immunology Terms and Conditions